E-viri
PDF
Recenzirano
Odprti dostop
-
Choueiri, Toni K; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T; Zurawski, Bogdan; Oyervides Juárez, Victor M; Hsieh, James J; Basso, Umberto; Shah, Amishi Y; Suárez, Cristina; Hamzaj, Alketa; Goh, Jeffrey C; Barrios, Carlos; Richardet, Martin; Porta, Camillo; Kowalyszyn, Rubén; Feregrino, Juan P; Żołnierek, Jakub; Pook, David; Kessler, Elizabeth R; Tomita, Yoshihiko; Mizuno, Ryuichi; Bedke, Jens; Zhang, Joshua; Maurer, Matthew A; Simsek, Burcin; Ejzykowicz, Flavia; Schwab, Gisela M; Apolo, Andrea B; Motzer, Robert J
New England journal of medicine/The New England journal of medicine, 03/2021, Letnik: 384, Številka: 9Journal Article
In a randomized trial involving patients with previously untreated advanced renal-cell carcinoma, nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free and overall survival and the likelihood of response. A total of 19.7% of the patients in the combination group discontinued one or both of the trial drugs prematurely.
